ASH 2021 | Advances in treating amyloidosis with botulinum toxin
Maria Moscvin
• 13 Dec 2021
Maria Moscvin, MD, Brigham and Women’s Hospital, Boston, MA, describes the next steps in assessing botulinum neurotoxin as a treatment for amyloidosis, which targets immunoglobulin free light chains (FLC). Further research is required in in vivo models and developing a hydrogel scaffold coated with stromal cells will enable to mimic the microenvironment of amyloidosis cells. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
